Literature DB >> 29441278

Re: American Gastroenterological Association Institute Guideline on therapeutic drug monitoring in inflammatory bowel disease.

Andrew S Day1.   

Abstract

Entities:  

Year:  2018        PMID： 29441278      PMCID： PMC5803018          DOI： 10.21037/tp.2017.12.03

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN： 2224-4336


× No keyword cloud information.
  15 in total

1.  Therapeutic drug monitoring was helpful in guiding the decision-making process for children receiving infliximab for inflammatory bowel disease.

Authors:  Vini Deora; Justin Kozak; Mohamed El-Kalla; Hien Q Huynh; Wael El-Matary
Journal:  Acta Paediatr       Date:  2017-08-24       Impact factor: 2.299

Review 2.  American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel Disease.

Authors:  Joseph D Feuerstein; Geoffrey C Nguyen; Sonia S Kupfer; Yngve Falck-Ytter; Siddharth Singh
Journal:  Gastroenterology       Date:  2017-08-03       Impact factor: 22.682

Review 3.  Fecal biomarkers in inflammatory bowel disease.

Authors:  Robert N Lopez; Steven T Leach; Daniel A Lemberg; Gilles Duvoisin; Richard B Gearry; Andrew S Day
Journal:  J Gastroenterol Hepatol       Date:  2017-03       Impact factor: 4.029

4.  Infliximab, azathioprine, or combination therapy for Crohn's disease.

Authors:  Jean Frédéric Colombel; William J Sandborn; Walter Reinisch; Gerassimos J Mantzaris; Asher Kornbluth; Daniel Rachmilewitz; Simon Lichtiger; Geert D'Haens; Robert H Diamond; Delma L Broussard; Kezhen L Tang; C Janneke van der Woude; Paul Rutgeerts
Journal:  N Engl J Med       Date:  2010-04-15       Impact factor: 91.245

5.  Thiopurine metabolite monitoring in paediatric inflammatory bowel disease.

Authors:  C Y Ooi; T D Bohane; D Lee; D Naidoo; A S Day
Journal:  Aliment Pharmacol Ther       Date:  2007-04-15       Impact factor: 8.171

6.  A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel disease.

Authors:  Elaheh Vahabnezhad; Shervin Rabizadeh; Marla C Dubinsky
Journal:  Inflamm Bowel Dis       Date:  2014-04       Impact factor: 5.325

7.  Concomitant Use of Immunomodulators Affects the Durability of Infliximab Therapy in Children With Crohn's Disease.

Authors:  Victoria Grossi; Trudy Lerer; Anne Griffiths; Neal LeLeiko; Jose Cabrera; Anthony Otley; James Rick; David Mack; Athos Bousvaros; Joel Rosh; Andrew Grossman; Shehzaad Saeed; Marsha Kay; Brendan Boyle; Maria Oliva-Hemker; David Keljo; Marian Pfefferkorn; William Faubion; Michael D Kappelman; Boris Sudel; James Markowitz; Jeffrey S Hyams
Journal:  Clin Gastroenterol Hepatol       Date:  2015-04-21       Impact factor: 11.382

Review 8.  Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.

Authors:  Marla C Dubinsky
Journal:  Clin Gastroenterol Hepatol       Date:  2004-09       Impact factor: 11.382

Review 9.  Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.

Authors:  N Mitrev; N Vande Casteele; C H Seow; J M Andrews; S J Connor; G T Moore; M Barclay; J Begun; R Bryant; W Chan; C Corte; S Ghaly; D A Lemberg; V Kariyawasam; P Lewindon; J Martin; R Mountifield; G Radford-Smith; P Slobodian; M Sparrow; C Toong; D van Langenberg; M G Ward; R W Leong
Journal:  Aliment Pharmacol Ther       Date:  2017-10-13       Impact factor: 8.171

10.  Biologics in paediatric Crohn's disease.

Authors:  Oliver Gouldthorpe; Anthony G Catto-Smith; George Alex
Journal:  Gastroenterol Res Pract       Date:  2011-11-17       Impact factor: 2.260
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.